We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss
Read MoreHide Full Article
Shares of Epizyme Inc. fell about 23.7% after it announced third-quarter 2020 results. The company incurred a loss of 55 cents per share in third-quarter 2020, which was narrower than the Zacks Consensus Estimate of a loss of 61 cents but wider than the year-ago loss of 40 cents. However, Shares of Epizyme have plunged 58% in the year so far compared with the industry’s decline of 1.4%.
Total revenues for the third quarter of 2020 were $3.6 million, which missed the Zacks Consensus Estimate of $6 million and down from the year-ago revenues of $5.7 million.
Quarter in Detail
Tazverik became commercially available to patients on Feb 1, 2020, following its accelerated approval in January for the treatment of metastatic or locally advanced Epithelioid Sarcoma (ES).
Tazverik generated net product revenues in both ESand FL of $3.4 million in the third quarter, with growth largely driven by the FDA approval of the drug in relapsed or refractoryFL on Jun 18, 2020. However, during the third quarter, the COVID-19 pandemic continued to negatively impact FL patient visits to physicians, new patient starts across all lines of treatmentand the ability of Epizyme’s field-based teams to fully access FL prescribers.
Collaboration revenues in third-quarter 2020, earned as part of the company’s alliance with Boehringer Ingelheim, were $0.1 million.
Research and development expenses decreased to $23.5 million from $25.3 million in the year-ago quarter.
SG&A expenses increased to $26.2 million from $14.5 million.
Epizyme had $279.9 million of cash, cash equivalents and marketable securities as of September 30 compared with $322.1 million as of Jun 20. Epizyme and Pharmakon Advisors, an affiliate of Royalty Pharma, expanded their original loan agreement established in November 2019, enabling Epizyme to draw down an additional $150 million from the loan facility, subject to customary closing conditions. The company expects its existing cash, cash equivalents and marketable securities combined with the proceeds from the loan facility tofund its operations untilat least 2023.
Pipeline Update
Epizyme completed enrollment in the safety run-in portion of its combination study of Tazverikin metastatic castration-resistant prostate cancer (mCRPC) and the initiation of the efficacy expansion stage is planned for early 2021. The company expects to report safety and efficacy data from the safety run-in portion of the study at a medical meeting in 2021.
While approval of Tazverik is a great boost for Epizyme, competition is stiff from bigwigs like Novartis (NVS - Free Report) , Pfizer (PFE - Free Report) and Merck (MRK - Free Report) . Hence, gaining market share in its targeted space will be a daunting task for the company.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Epizyme's (EPZM) Q3 Loss Narrower Than Expected, Sales Miss
Shares of Epizyme Inc. fell about 23.7% after it announced third-quarter 2020 results. The company incurred a loss of 55 cents per share in third-quarter 2020, which was narrower than the Zacks Consensus Estimate of a loss of 61 cents but wider than the year-ago loss of 40 cents. However, Shares of Epizyme have plunged 58% in the year so far compared with the industry’s decline of 1.4%.
Total revenues for the third quarter of 2020 were $3.6 million, which missed the Zacks Consensus Estimate of $6 million and down from the year-ago revenues of $5.7 million.
Quarter in Detail
Tazverik became commercially available to patients on Feb 1, 2020, following its accelerated approval in January for the treatment of metastatic or locally advanced Epithelioid Sarcoma (ES).
Tazverik generated net product revenues in both ESand FL of $3.4 million in the third quarter, with growth largely driven by the FDA approval of the drug in relapsed or refractoryFL on Jun 18, 2020. However, during the third quarter, the COVID-19 pandemic continued to negatively impact FL patient visits to physicians, new patient starts across all lines of treatmentand the ability of Epizyme’s field-based teams to fully access FL prescribers.
Collaboration revenues in third-quarter 2020, earned as part of the company’s alliance with Boehringer Ingelheim, were $0.1 million.
Research and development expenses decreased to $23.5 million from $25.3 million in the year-ago quarter.
SG&A expenses increased to $26.2 million from $14.5 million.
Epizyme had $279.9 million of cash, cash equivalents and marketable securities as of September 30 compared with $322.1 million as of Jun 20. Epizyme and Pharmakon Advisors, an affiliate of Royalty Pharma, expanded their original loan agreement established in November 2019, enabling Epizyme to draw down an additional $150 million from the loan facility, subject to customary closing conditions. The company expects its existing cash, cash equivalents and marketable securities combined with the proceeds from the loan facility tofund its operations untilat least 2023.
Pipeline Update
Epizyme completed enrollment in the safety run-in portion of its combination study of Tazverikin metastatic castration-resistant prostate cancer (mCRPC) and the initiation of the efficacy expansion stage is planned for early 2021. The company expects to report safety and efficacy data from the safety run-in portion of the study at a medical meeting in 2021.
While approval of Tazverik is a great boost for Epizyme, competition is stiff from bigwigs like Novartis (NVS - Free Report) , Pfizer (PFE - Free Report) and Merck (MRK - Free Report) . Hence, gaining market share in its targeted space will be a daunting task for the company.
Currently, Epizyme is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Epizyme, Inc. Price, Consensus and EPS Surprise
Epizyme, Inc. price-consensus-eps-surprise-chart | Epizyme, Inc. Quote
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>